Full Press Release Details
INmune Bio, Inc. Featured on Fox
News (VIDEO): STNF and Cytokine Storm
LA JOLLA, Calif, July 27, 2020
(GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company
focused on developing treatments that harness the patient's innate immune system to fight disease was featured on a
Fox Business News segment.
Fox Business News reports: "INmune
Bio CEO, President and acting CMO Dr. Raymond Tesi, M.D. talks about INmune Bio's proposed phase two human trials of possible treatment
of coronavirus patients using an anti-inflammatory drug and addresses the effort for lower drug costs."
To watch the full interview, please
visit the link below: https://video.foxbusiness.com/v/6174850319001/?playlist_id=937116503001#sp=show-clips
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly
traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system
to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology
to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF
is currently being developed for COVID-19 complications (Quellor ), cancer (INB03 ), Alzheimer's (XPro595), and
NASH (LIVNate ). The Natural Killer Cell Priming Platform includes INKmune aimed at priming the patient's NK
cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision
medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn
more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages
and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation
Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number
of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these risks and uncertainties. INB03 , XPro1595, LIVNate ,
Quellor and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved
and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are
beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual
future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating
to the Company's ability to produce more drug for clinical trials; the availability of substantial additional funding for
the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization;
and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange
Commission, including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the
Company's Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order
to reflect any event or circumstance that may arise after the date of this release.
David Moss, CFO (858) 964-3720
James Carbonara (646) 755-7412